Skip to main content

Table 2 Subgroup analysis of ICU days, MV days, and RRT days in the included randomized controlled trials

From: Comparison between watchful waiting strategy and early initiation of renal replacement therapy in the critically ill acute kidney injury population: an updated systematic review and meta-analysis

Outcome/subgroup

No. of studies

No. of patients

Pooled mean difference (95% CI)

I2 (%)

P for subgroup difference

ICU LOS

     

 Population

    

0.518

  Medical

1

488

1.00 (− 0.91 to 2.91)

0

 

  Surgical

1

231

− 0.50 (− 4.65 to 3.65)

0

 

  Mixed

4

943

− 0.35 (− 1.77 to 1.08)

0

 

 NGAL-based

    

0.350

  No

3

1213

0.30 (− 0.89 to 1.49)

0

 

  Yes

3

449

− 1.20 (− 4.12 to 1.72)

0

 

 Emergent need for RRT

    

0.470

  Included

1

106

− 2.00 (− 7.78 to 3.78)

0

 

  Excluded

5

1556

0.17 (− 0.95 to 1.29)

0

 

MV days

     

 Population

    

0.054

  Medical

1

488

1.00 (− 1.63 to 3.63)

0

 

  Surgical

1

231

− 2.31 (− 4.50 to − 0.13)

0

 

  Mixed

4

883

− 7.14 (− 15.05 to 0.76)

89

 

 NGAL-based

    

0.101

  No

3

1213

− 0.28 (− 2.01 to 1.45)

0

 

  Yes

3

389

− 9.44 (− 20.25 to 1.38)

92.2

 

 Emergent need for RRT

    

0.269

  Included

2

146

− 13.28 (− 34.83 to 8.28)

94.6

 

  Excluded

4

1456

− 1.09 (− 2.78 to 0.60)

29.7

 

RRT days

     

 Population

    

0.001

  Medical

1

488

2.00 (1.21 to 2.79)

0

 

  Surgical

1

231

− 16.00 (− 28.57 to − 3.43)

0

 

  Mixed

4

985

− 5.19 (− 11.25 to 0.86)

93

 

 NGAL-based

    

0.031#

  No

3

1315

1.46 (0.21 to 2.71)

60.4

 

  Yes

3

389

− 14.38 (− 28.74 to − 0.02)

88.1

 

 Emergent need for RRT

    

< 0.001

  Included

1

40

− 24.50 (− 32.84 to − 16.16)

0

 

  Excluded

5

1664

0.45 (− 1.47 to 2.37)

74.5

 
  1. LOS length of stay, NGAL neutrophil gelatinase-associated lipocalin, RRT renal replacement therapy
  2. #This result was nonsignificant at P < .0042 (0.05/12) if a Bonferroni adjustment was made for alpha error correction